Dare Bioscience

Dare Bioscience CROIC

The Cash Return on Invested Capital (CROIC) of Dare Bioscience (DARE) as of Nov 2, 2026 is -186.79 %. In the previous year, Cash Return on Invested Capital (CROIC) was -102.38 % — a change of 82.45% (lower).

CROIC

-186.79 %

YoY

82.45%

Last updated:

Cash Return on Invested Capital (CROIC) of Dare Bioscience is 2025 -186.79 % . Cash Return on Invested Capital (CROIC) of Dare Bioscience was 2024 -102.38 % . It decreases by 82.45% lower compared to the previous year.

The Dare Bioscience CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-152.83 USD
Jan 1, 2019
-1,074.14 USD
Jan 1, 2020
6,394.80 USD
Jan 1, 2021
-73.74 USD
Jan 1, 2022
-156.47 USD
Jan 1, 2023
1,083.84 USD
Jan 1, 2024
-102.38 USD
Jan 1, 2025
-186.79 USD
The Dare Bioscience CROIC history
YEARCROICYoY
-186.79 %+82.45%
-102.38 %-109.45%
1,083.84 %-792.69%
-156.47 %+112.18%
-73.74 %-101.15%
6,394.80 %-695.34%
-1,074.14 %+602.84%
-152.83 %+696.07%
-19.20 %-85.39%
-131.39 %+181.88%
-46.61 %+17.09%
-39.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Cash Return on Invested Capital (CROIC) of Dare Bioscience is -186.79 % in 2025.

Cash Return on Invested Capital (CROIC) of Dare Bioscience changed from -102.38 % to -186.79 %, representing a 82.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Dare Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Dare Bioscience

All Key Metrics — Dare Bioscience